Skip over navigation
Directory
Directory Search
Jobs
Job Search
Post a Job
Patient
Patient Resources
Drug Development
History
Genealogy
Toons & Teasers
About
Advertising
Home
Quick Links
Directory
Job Search
Toons & Teasers
Advertising
LifeScienceHistory.com - Check us out on Instagram
Industry News
Search Articles:
New data show Amgen's Repathaź (evolocumab) significantly reduced LDL-C and non-HDL-C
Amgen announced new data that show Repathaź (evolocumab) significantly reduced low-density lipoprotein cholesterol and non-high density lipoprotein cholesterol in patients with Type 2 diabetes and hypercholesterolemia or mixed dyslipidemia.
June 23, 2018
More...
Email This Page
to a Friend
Print This
Page